Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for lung cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Combining smoking cessation interventions with LDCT lungcancer screening: A systematic review Providing smoking cessation treatment with annual low dose CT (LDCT) screening offers an opportunity to reduce smoking-related morbidity and mortality. However, the optimal approach for delivering cessation interventions in the LDCT screening context is unknown. We searched for randomized controlled trials and observational studies with a control group testing a smoking cessation intervention among
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell LungCancer With PD-L1 Tumor Proportion Score of 50% or Greater In the randomized, open-label, phase III KEYNOTE-024 study, pembrolizumab significantly improved progression-free survival and overall survival (OS) compared with platinum-based chemotherapy in patients with previously untreated advanced non-small-cell lungcancer (NSCLC) with a programmed death ligand 1 tumor proportion
Exercise training for advanced lungcancer. Patients with advanced lungcancer have a high symptom burden, which is often complicated by coexisting conditions. These issues, combined with the indirect effects of cancer treatment, can cumulatively lead patients to continued deconditioning and low exercise capacity. This is a concern as exercise capacity is considered a measure of whole body health, and is critical in a patient's ability to participate in life activities and tolerate difficult (...) treatments. There is evidence that exercise training improves exercise capacity and other outcomes, such as muscle force and health-related quality of life (HRQoL), in cancer survivors. However, the effectiveness of exercise training on these outcomes in people with advanced lungcancer is currently unclear.The primary aim of this review was to investigate the effects of exercise training on exercise capacity in adults with advanced lungcancer. Exercise capacity was defined as the six-minute walk
Crizotinib (Alunbrig) - for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lungcancer (NSCLC) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization
Short-Term Readmissions After Open, Thoracoscopic, and Robotic Lobectomy for LungCancer Based on the Nationwide Readmissions Database Readmission after surgery is an established surrogate indicator of quality of care. We aimed to compare short-term readmission rates and patient outcomes between open, video-assisted thoracoscopic (VATS), and robotic lobectomies in the Nationwide Readmissions Database (NRD).Adults who underwent open, VATS, or robotic lobectomy for lungcancer from 2010 to 2014 (...) were evaluated. Propensity-matched analysis was used to assess differences in readmission characteristics, GDP-adjusted cost, and mortality.Of the 129,539 lobectomies for lungcancer, 74,493 (57.5%) were open, 48,185 (37.2%) VATS, and 6861 (5.3%) robotic. Open surgery was associated with significantly higher readmission rate (10.5 vs 9.3%, p < 0.001), mortality (2 vs 1.2%, p < 0.001), index hospitalization cost [$21,846 (16,158-31,034) vs $20,779 (15,619-27,920), p < 0.001], and length of stay [6
Persisting new nodules in incidence rounds of the NELSON CT lungcancer screening study The US guidelines recommend low-dose CT (LDCT) lungcancer screening for high-risk individuals. New solid nodules after baseline screening are common and have a high lungcancer probability. Currently, no evidence exists concerning the risk stratification of non-resolving new solid nodules at first LDCT screening after initial detection.In the Dutch-Belgian Randomized LungCancer Screening (NELSON) trial (...) nodules were resolving, leaving 356 (52%) participants with a non-resolving new solid nodule, of whom 25 (7%) were diagnosed with lungcancer. At first screening after initial detection, volume doubling time (VDT), volume, and VDT combined with a predefined ≥200 mm3 volume cut-off had high discrimination for lungcancer (VDT, area under the curve (AUC): 0.913; volume, AUC: 0.875; VDT and ≥200 mm3 combination, AUC: 0.939). Classifying a new solid nodule with either ≤590 days VDT or ≥200 mm3 volume
Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell LungCancer: ECOG-ACRIN 2511 Study Veliparib, a poly (ADP ribose) polymerase inhibitor, potentiated standard chemotherapy against small-cell lungcancer (SCLC) in preclinical studies. We evaluated the combination of veliparib with cisplatin and etoposide (CE; CE+V) doublet in untreated, extensive-stage SCLC (ES-SCLC).Patients with ES-SCLC, stratified by sex and serum
Whole brain radiotherapy provides little benefit for lungcancer that has spread Whole brain radiotherapy provides little benefit for lungcancer that has spread Discover Portal Discover Portal Whole brain radiotherapy provides little benefit for lungcancer that has spread Published on 10 January 2017 doi: Radiotherapy to the whole brain makes little difference to people with the commonest type of lungcancer that has spread to the brain and cannot be operated on. This mainly UK-based trial (...) found no difference in overall survival and quality of life among people who had whole brain radiotherapy plus usual supportive care compared with people who received supportive care alone. This is the largest trial to assess the effect of this treatment in people with non-small cell lungcancer and multiple brain metastases (cancer deposits in the brain). Practice has been changing since early results of the trial were released. The final results reinforce the message that this treatment has little
Postoperative radiotherapy reduces survival after surgery to remove non-small cell lungcancer Postoperative radiotherapy reduces survival after surgery to remove non-small cell lungcancer Discover Portal Discover Portal Postoperative radiotherapy reduces survival after surgery to remove non-small cell lungcancer Published on 28 February 2017 doi: Postoperative radiotherapy increases the risk of death by 18% for patients with non-small cell lungcancer that has been removed by surgery. Just (...) recurrence rates. Most of the trials are from over 30 years ago, so there is the possibility that newer radiotherapy techniques may be less harmful. Nevertheless, this review provides the best evidence to date that postoperative radiotherapy may not be appropriate as a routine treatment for non-small cell lungcancer. Share your views on the research. Why was this study needed? Lungcancer is the second most common cancer in the UK with 37,453 new cases registered in 2014. The majority of lungcancers
Circulating high sensitivity C reactive protein concentrations and risk of lungcancer: nested case-control study within LungCancer Cohort Consortium. To conduct a comprehensive analysis of prospectively measured circulating high sensitivity C reactive protein (hsCRP) concentration and risk of lungcancer overall, by smoking status (never, former, and current smokers), and histological sub-type.Nested case-control study.20 population based cohort studies in Asia, Europe, Australia (...) , and the United States.5299 patients with incident lungcancer, with individually incidence density matched controls.Circulating hsCRP concentrations in prediagnostic serum or plasma samples.Incident lungcancer diagnosis.A positive association between circulating hsCRP concentration and the risk of lungcancer for current (odds ratio associated with a doubling in hsCRP concentration 1.09, 95% confidence interval 1.05 to 1.13) and former smokers (1.09, 1.04 to 1.14) was observed, but not for never smokers (P
A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non-small cell lungcancer Stereotactic body radiation therapy is the preferred treatment modality for patients with inoperable early-stage non-small cell lungcancer. However, comparative outcomes between stereotactic body radiation therapy and surgery for high-risk patients remain controversial. The primary aim of the present meta-analysis was to assess overall survival in matched (...) and unmatched patient cohorts undergoing stereotactic body radiation therapy or surgery. Secondary end points included cancer-specific survival, disease-free survival, disease recurrence, and perioperative outcomes.A systematic review of relevant studies was performed through online databases using predefined criteria. The most updated studies were selected for meta-analysis according to unmatched and matched patient cohorts.Thirty-two studies were identified in the systematic review, and 23 were selected
Management of anlotinib-related adverse events in patients with advanced non-small cell lungcancer: Experiences in ALTER-0303. Anlotinib is an oral tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor, fibroblast growth factor receptor, platelet-derived growth factor receptor, and stem cell factor receptor (c-Kit). In the phase III ALTER-0303 trial (Clinical Trial Registry ID: NCT 02388919), anlotinib significantly improved overall survival versus placebo in advanced (...) non-small cell lungcancer patients who had received at least two previous chemotherapy and epidermal growth factor receptor/anaplastic lymphoma kinase targeted therapy regimens. This study summarized adverse event management in this trial.Patients were randomized (2:1) to anlotinib or placebo up to progression or intolerable toxicity. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 and managed by investigators. Key
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic non-small cell lungcancer SPECIAL ARTICLE Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lungcancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS Y.-L. Wu 1 * , D. Planchard 2 ,S.Lu 3 , H. Sun 4 , N. Yamamoto 5 , D.-W. Kim 6 , D. S. W. Tan 7 , J. C.-H. Yang 8 , M. Azrif 9 , T. Mitsudomi 10 , K. Park 11 , R. A. Soo (...) 12 , J. W. C. Chang 13 , A. Alip 14 , S. Peters 15 & J.-Y. Douillard 16 1 Guangdong LungCancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, P.R. China; 2 Department of Medical Oncology, Thoracic Group, Gustave Roussy, Villejuif, France; 3 Shanghai Chest Hospital, Shanghai; 4 Guangdong LungCancer Institute, Guangdong LungCancer Institute, Guangdong General Hospital, School of Medicine, South China University of Technology, Guangzhou, P.R. China; 5
ASTRO Guideline on Palliative Radiation Therapy for Non-small Cell LungCancer (NSCLC) - Update Palliative thoracic radiation therapy for non-small cell lungcancer: 2018 Update of an American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline - Practical Radiation Oncology Email/Username: Password: Remember me Search Terms Search within Search Share this page: Volume 8, Issue 4, Pages 245–250 Palliative thoracic radiation therapy for non-small cell lungcancer: 2018 Update (...) Accepted: February 19, 2018 ; Received: February 6, 2018 ; Abstract Purpose To revise the recommendation on the use of concurrent chemotherapy (CC) with palliative thoracic external beam radiation therapy (EBRT) made in the original 2011 American Society for Radiation Oncology guideline on palliative thoracic radiation for lungcancer. Methods and materials Based on a systematic PubMed search showing new evidence for this key question, the task force felt an update was merited. Guideline
The value of Lunx-mRNA positive expression and clinicopathology in non-small cell lungcancer: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files
The association between quality of life and unmet supportive care needs in patients with lungcancer and their carers Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated
The optimal treatment for non-small cell lungcancer with brain metastasis: a network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external
The optimal treatment for metastatic non-small cell lungcancer without brain metastasis: a network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated